OX26-cojugated Gangliosilated Liposomes to Improve the Post-ischemic Therapeutic Effect of CDP-choline

Overview

Journal Drug Deliv Transl Res

Publisher Springer

Specialty Pharmacology

Date 2024 Mar 13

PMID 38478324

Authors

Nicola dAvanzo

Donatella Paolino

Antonella Barone

Luigi Ciriolo

Antonia Mancuso

Maria Chiara Christiano

Anna Maria Tolomeo

Christian Celia

Xiaoyong Deng

Massimo Fresta

Affiliations

Soon will be listed here.

Abstract

Cerebrovascular impairment represents one of the main causes of death worldwide with a mortality rate of 5.5 million per year. The disability of 50% of surviving patients has high social impacts and costs in long period treatment for national healthcare systems. For these reasons, the efficacious clinical treatment of patients, with brain ischemic stroke, remains a medical need. To this aim, a liposome nanomedicine, with monosialic ganglioside type 1 (GM1), OX26 (an anti-transferrin receptor antibody), and CDP-choline (a neurotrophic drug) (CDP-choline/OX26Lip) was prepared. CDP-choline/OX26Lip were prepared by a freeze and thaw method and then extruded through polycarbonate filters, to have narrow size distributed liposomes of ~80 nm. CDP-choline/OX26Lip were stable in human serum, they had suitable pharmacokinetic properties, and 30.0 ± 4.2% of the injected drug was still present in the blood stream 12 h after its systemic injection. The post-ischemic therapeutic effect of CDP-choline/OX26Lip is higher than CDP-choline/Lip, thus showing a significantly high survival rate of the re-perfused post-ischemic rats, i.e. 96% and 78% after 8 days. The treatment with CDP-choline/OX26Lip significantly decreased the peroxidation rate of ~5-times compared to CDP-choline/Lip; and the resulting conjugated dienes, that was 13.9 ± 1.1 mmol/mg proteins for CDP-choline/Lip and 3.1 ± 0.8 for CDP-choline/OX26Lip. OX26 increased the accumulation of GM1-liposomes in the brain tissues and thus the efficacious of CDP-choline. Therefore, this nanomedicine may represent a strategy for the reassessment of CDP-choline to treat post-ischemic events caused by brain stroke, and respond to a significant clinical need.

Citing Articles

Double Peptide-Functionalized Carboxymethyl Chitosan-Coated Liposomes Loaded with Dexamethasone as a Potential Strategy for Active Targeting Drug Delivery.

Iftode L, Cadinoiu A, Rata D, Atanase L, Vochita G, Radulescu L Int J Mol Sci. 2025; 26(3).

PMID: 39940692 PMC: 11816442. DOI: 10.3390/ijms26030922.

Innovative Approaches to Enhancing the Biomedical Properties of Liposomes.

Dejeu I, Vicas L, Marian E, Ganea M, Frent O, Maghiar P Pharmaceutics. 2025; 16(12.

PMID: 39771504 PMC: 11728823. DOI: 10.3390/pharmaceutics16121525.

Metabolomics study of APETx2 post-conditioning on myocardial ischemia-reperfusion injury.

Li J, Wei Y, Wang Y, Zhang Y, Xu Y, Ma H Front Pharmacol. 2024; 15:1470142.

PMID: 39712499 PMC: 11658994. DOI: 10.3389/fphar.2024.1470142.

Unraveling the impact of different liposomal formulations on the plasma protein corona composition might give hints on the targeting capability of nanoparticles.

Imperlini E, Di Marzio L, Cevenini A, Costanzo M, dAvanzo N, Fresta M Nanoscale Adv. 2024; 6(17):4434-4449.

PMID: 39170967 PMC: 11334990. DOI: 10.1039/d4na00345d.

References

Paul S, Candelario-Jalil E . Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies. Exp Neurol. 2020; 335:113518. PMC: 7869696. DOI: 10.1016/j.expneurol.2020.113518. View

Ma V, Chan L, Carruthers K . Incidence, prevalence, costs, and impact on disability of common conditions requiring rehabilitation in the United States: stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, osteoarthritis, rheumatoid arthritis, limb loss, and.... Arch Phys Med Rehabil. 2014; 95(5):986-995.e1. PMC: 4180670. DOI: 10.1016/j.apmr.2013.10.032. View

Flynn R, MacWalter R, Doney A . The cost of cerebral ischaemia. Neuropharmacology. 2008; 55(3):250-6. DOI: 10.1016/j.neuropharm.2008.05.031. View

Rochmah T, Rahmawati I, Dahlui M, Budiarto W, Bilqis N . Economic Burden of Stroke Disease: A Systematic Review. Int J Environ Res Public Health. 2021; 18(14). PMC: 8307880. DOI: 10.3390/ijerph18147552. View

George M . Risk Factors for Ischemic Stroke in Younger Adults: A Focused Update. Stroke. 2020; 51(3):729-735. PMC: 7112557. DOI: 10.1161/STROKEAHA.119.024156. View

Tuo Q, Zhang S, Lei P . Mechanisms of neuronal cell death in ischemic stroke and their therapeutic implications. Med Res Rev. 2021; 42(1):259-305. DOI: 10.1002/med.21817. View

Nozohouri S, Sifat A, Vaidya B, Abbruscato T . Novel approaches for the delivery of therapeutics in ischemic stroke. Drug Discov Today. 2020; 25(3):535-551. PMC: 7490972. DOI: 10.1016/j.drudis.2020.01.007. View

Shi K, Tian D, Li Z, Ducruet A, Lawton M, Shi F . Global brain inflammation in stroke. Lancet Neurol. 2019; 18(11):1058-1066. DOI: 10.1016/S1474-4422(19)30078-X. View

Kalogeris T, Baines C, Krenz M, Korthuis R . Ischemia/Reperfusion. Compr Physiol. 2017; 7(1):113-170. PMC: 5648017. DOI: 10.1002/cphy.c160006. View

10.

Fisher M, Savitz S . Pharmacological brain cytoprotection in acute ischaemic stroke - renewed hope in the reperfusion era. Nat Rev Neurol. 2022; 18(4):193-202. PMC: 8788909. DOI: 10.1038/s41582-021-00605-6. View

11.

Overgaard K . The effects of citicoline on acute ischemic stroke: a review. J Stroke Cerebrovasc Dis. 2014; 23(7):1764-9. DOI: 10.1016/j.jstrokecerebrovasdis.2014.01.020. View

12.

Alvarez-Sabin J, Roman G . Citicoline in vascular cognitive impairment and vascular dementia after stroke. Stroke. 2010; 42(1 Suppl):S40-3. DOI: 10.1161/STROKEAHA.110.606509. View

13.

Davalos A, Alvarez-Sabin J, Castillo J, Diez-Tejedor E, Ferro J, Martinez-Vila E . Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet. 2012; 380(9839):349-57. DOI: 10.1016/S0140-6736(12)60813-7. View

14.

Clark W, Clark T . Stroke: Treatment for acute stroke--the end of the citicoline saga. Nat Rev Neurol. 2012; 8(9):484-5. DOI: 10.1038/nrneurol.2012.166. View

15.

Adibhatla R . Citicoline in stroke and TBI clinical trials. Nat Rev Neurol. 2013; 9(3):173. DOI: 10.1038/nrneurol.2012.166-c1. View

16.

Fresta M, WEHRLI E, Puglisi G . Enhanced therapeutic effect of cytidine-5'-diphosphate choline when associated with GM1 containing small liposomes as demonstrated in a rat ischemia model. Pharm Res. 1995; 12(11):1769-74. DOI: 10.1023/a:1016234226404. View

17.

Fresta M, Puglisi G . Reduction of maturation phenomenon in cerebral ischemia with CDP-choline-loaded liposomes. Pharm Res. 2000; 16(12):1843-9. DOI: 10.1023/a:1018999225435. View

18.

Ghosh S, Das N, Mandal A, Dungdung S, Sarkar S . Mannosylated liposomal cytidine 5' diphosphocholine prevent age related global moderate cerebral ischemia reperfusion induced mitochondrial cytochrome c release in aged rat brain. Neuroscience. 2010; 171(4):1287-99. DOI: 10.1016/j.neuroscience.2010.09.049. View

19.

Liu H, Jablonska A, Li Y, Cao S, Liu D, Chen H . Label-free CEST MRI Detection of Citicoline-Liposome Drug Delivery in Ischemic Stroke. Theranostics. 2016; 6(10):1588-600. PMC: 4955057. DOI: 10.7150/thno.15492. View

20.

Birolini G, Valenza M, Ottonelli I, Passoni A, Favagrossa M, Duskey J . Insights into kinetics, release, and behavioral effects of brain-targeted hybrid nanoparticles for cholesterol delivery in Huntington's disease. J Control Release. 2021; 330:587-598. DOI: 10.1016/j.jconrel.2020.12.051. View